Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC. Contribution of IASLC recommendations-Reference-Cited by-同舟云学术

Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC. Contribution of IASLC recommendations

Published:2021-11-24 Issue:11 Volume:12 Page:1047-1063
ISSN:2218-4333
Container-title:World Journal of Clinical Oncology
language:
Short-container-title:WJCO

Author:

Muñoz-Guglielmetti Diego,Sanchez-Lorente David,Reyes Roxana,Martinez Daniel,Lucena Carmen,Boada Marc,Paredes Pilar,Parera-Roig Marta,Vollmer Ivan,Mases Joel,Martin-Deleon Roberto,Castillo Sergi,Benegas Mariana,Muñoz Silvia,Mayoral Maria,Cases Carla,Mollà Meritxell,Casas Francesc

Publisher

Baishideng Publishing Group Inc.

Subject

Oncology

Reference39 articles.

1. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

2. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment

3. Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy

4. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

5. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating Durvalumab with Neoadjuvant Chemoradiation and Surgery in Patients with Borderline Resectable Stage III Non-Small Cell Lung Cancer: A Retrospective Case Series;2024-02-22

2. Neoadjuvant Nivolumab and Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Retrospective Study;Cancer Management and Research;2022-02